EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA–Clinical Science

Daniel Eisenson iD, Emilien Seizilles de Mazancourt iD, Joseph Ladowski iD, Evelyn J Salvaris iD, Konrad Fischer iD, Antonio Citro iD, Liaoran Wang iD, Alessia Giarraputo iD, Margaret R Connolly iD, Alban E Longchamp iD, Corbin E Goerlich iD, Jeffrey Stern iD und 1 weitere

Xenotransplantation · 2026-11 · 33 (6)

DOI: 10.1111/xen.70178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, online erschienen am 17.11.2026. Verfasst von Daniel Eisenson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplantation, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Heterografts. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2025 International Xenotransplantation Association (IXA) Congress in Geneva, convened in parallel with World Health Organization meetings on xenotransplantation guidance, marked a transition in clinical xenotransplantation from demonstrating that pig organs can function in humans to defining how graft injury is detected, interpreted, and managed in real time. We synthesize the major clinical themes that emerged from the meeting across kidney, heart, liver, and lung xenotransplantation. In kidney xenotransplantation, the NYU and Massachusetts General Hospital living‐recipient experiences now delineate two complementary injury patterns—antibody‐ and complement‐driven with a membranoproliferative, IgA‐positive, innate‐rich phenotype, and T cell–mediated with persistent innate immune activation—both converging on macrophage and NK‐cell biology that conventional immunosuppression does not address. The first registration‐supporting Phase 1/2/3 trial of a 10‐gene‐edited xenokidney (EXPAND) has begun, framed by IXA position‐paper recommendations and supported by recent FDA approvals. In cardiac xenotransplantation, real‐time complement‐function monitoring, global longitudinal strain, and donor‐derived cell‐free DNA emerge as an actionable surveillance toolkit, while other allotransplant biomarkers translate poorly. In liver xenotransplantation, extracorporeal cross‐circulation and the first preliminary data describing auxiliary pig‐to‐human liver transplant (171‐day survival) position porcine livers as bridge‐support platforms rather than definitive replacements. Lung xenotransplantation remains confined to ex vivo perfusion and short‐term preclinical models. Cross‐cutting priorities include donor‐pig design and individual graft phenotyping that accounts for transgene expression heterogeneity, prospectively validated multimodal monitoring, management of nephrotic‐range proteinuria and associated urinary loss of biologic immunosuppressants, and dedicated registry, ethical, and patient‐engagement infrastructure to support trustworthy clinical expansion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation, HeterologousHeterograftsHumansAnimalsSwineGraft Rejection

Stichwörter der Autor:innen

clinical xenotransplantationdeceased human modelsgenetically modified pigsmachine perfusionxenotransplantation

Autor:innen und Institutionen

  • Division of Transplantation, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Urology, Saint Louis Hospital, Paris, France.
  • Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • Immunology Research Centre, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Institute of Surgical Research, Walter Brendel Center of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Daniel Eisenson, Emilien Seizilles de Mazancourt, Joseph Ladowski, Evelyn J Salvaris, Konrad Fischer, Antonio Citro, Liaoran Wang, Alessia Giarraputo, Margaret R Connolly, Alban E Longchamp, Corbin E Goerlich, Jeffrey Stern, Raphael P H Meier

Zitieren

APA

Eisenson, D., de Mazancourt, E. S., Ladowski, J., Salvaris, E. J., Fischer, K., Citro, A., Wang, L., Giarraputo, A., Connolly, M. R., Longchamp, A. E., Goerlich, C. E., Stern, J., & Meier, R. P. H. (2026). What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA–Clinical Science. Xenotransplantation, 33(6). https://doi.org/10.1111/xen.70178

Vancouver

Eisenson D, de Mazancourt ES, Ladowski J, Salvaris EJ, Fischer K, Citro A, et al. What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA–Clinical Science. Xenotransplantation. 2026;33(6). doi:10.1111/xen.70178

BibTeX
@article{Eisenson2026,
  author = {Eisenson, Daniel and de Mazancourt, Emilien Seizilles and Ladowski, Joseph and Salvaris, Evelyn J and Fischer, Konrad and Citro, Antonio and Wang, Liaoran and Giarraputo, Alessia and Connolly, Margaret R and Longchamp, Alban E and Goerlich, Corbin E and Stern, Jeffrey and Meier, Raphael P H},
  title = {What's Hot and What's New in Xenotransplantation From the Young Investigator Committee of the IXA–Clinical Science},
  journal = {Xenotransplantation},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/xen.70178}
}
Kostenlos starten →